LENZ Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	17.5	-	-	15	-
Gross Profit	17.5	-	-	15	-
Selling, General & Admin	60.86	28.81	12.93	4.36	2.47
Research & Development	24.54	29.8	59.5	21.13	4.22
Operating Expenses	85.4	58.61	72.43	25.48	6.69
Operating Income	-67.9	-58.61	-72.43	-10.48	-6.69
Interest & Investment Income	9.34	8.55	2.19	0	-
Other Non Operating Income (Expenses)	0.18	0.29	0.09	0.02	-0.87
Pretax Income	-58.38	-49.77	-70.15	-10.46	-7.56
Income Tax Expense	0.5	0	-0.18	0.35	-
Net Income	-58.88	-49.77	-69.97	-10.81	-7.56
Net Income to Common	-58.88	-49.77	-69.97	-10.81	-7.56
Shares Outstanding (Basic)	28	21	2	9	9
Shares Outstanding (Diluted)	28	21	2	9	9
Shares Change (YoY)	87.55%	986.27%	-79.28%	1.05%	-
EPS (Basic)	-2.11	-2.34	-35.71	-1.14	-0.81
EPS (Diluted)	-2.11	-2.34	-35.71	-1.14	-0.81
Free Cash Flow	-46.16	-59.86	-60.41	-4.13	-5.4
Free Cash Flow Per Share	-1.65	-2.81	-30.84	-0.44	-0.58
Gross Margin	100.00%	-	-	100.00%	-
Operating Margin	-388.00%	-	-	-69.89%	-
Profit Margin	-336.47%	-	-	-72.07%	-
Free Cash Flow Margin	-263.78%	-	-	-27.52%	-
EBITDA	-67.7	-58.55	-72.41	-10.48	-6.69
EBITDA Margin	-	-	-	-69.83%	-
D&A For EBITDA	0.21	0.06	0.02	0.01	0
EBIT	-67.9	-58.61	-72.43	-10.48	-6.69
EBIT Margin	-	-	-	-69.89%	-
Revenue as Reported	17.5	-	-	15	-

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q